189 related articles for article (PubMed ID: 34158057)
41. Pregnancy-associated plasma protein-A is a stronger predictor for adverse cardiovascular outcomes after acute coronary syndrome in type-2 diabetes mellitus.
Li WP; Neradilek MB; Gu FS; Isquith DA; Sun ZJ; Wu X; Li HW; Zhao XQ
Cardiovasc Diabetol; 2017 Apr; 16(1):45. PubMed ID: 28381225
[TBL] [Abstract][Full Text] [Related]
42. The Effect of Bromodomain and Extra-Terminal Inhibitor Apabetalone on Attenuated Coronary Atherosclerotic Plaque: Insights from the ASSURE Trial.
Shishikura D; Kataoka Y; Honda S; Takata K; Kim SW; Andrews J; Psaltis PJ; Sweeney M; Kulikowski E; Johansson J; Wong NCW; Nicholls SJ
Am J Cardiovasc Drugs; 2019 Feb; 19(1):49-57. PubMed ID: 30155718
[TBL] [Abstract][Full Text] [Related]
43. Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial.
Lopes RD; de Barros E Silva PGM; de Andrade Jesuíno I; Santucci EV; Barbosa LM; Damiani LP; Nakagawa Santos RH; Laranjeira LN; Dall Orto FTC; Beraldo de Andrade P; de Castro Bienert IR; Alexander JH; Granger CB; Berwanger O
JAMA Cardiol; 2018 Nov; 3(11):1113-1118. PubMed ID: 30264159
[TBL] [Abstract][Full Text] [Related]
44. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus.
Elharram M; Sharma A; White W; Bakris G; Rossignol P; Mehta C; Ferreira JP; Zannad F
Am Heart J; 2020 Nov; 229():40-51. PubMed ID: 32916607
[TBL] [Abstract][Full Text] [Related]
45. Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome.
Rossello X; Ferreira JP; Caimari F; Lamiral Z; Sharma A; Mehta C; Bakris G; Cannon CP; White WB; Zannad F
Clin Res Cardiol; 2021 Oct; 110(10):1612-1624. PubMed ID: 33929598
[TBL] [Abstract][Full Text] [Related]
46. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Zannad F; Cannon CP; Cushman WC; Bakris GL; Menon V; Perez AT; Fleck PR; Mehta CR; Kupfer S; Wilson C; Lam H; White WB;
Lancet; 2015 May; 385(9982):2067-76. PubMed ID: 25765696
[TBL] [Abstract][Full Text] [Related]
47. A risk score to predict postdischarge bleeding among acute coronary syndrome patients undergoing percutaneous coronary intervention: BRIC-ACS study.
Chen Y; Yin T; Xi S; Zhang S; Yan H; Tang Y; Qian J; Chen J; Su X; Du Z; Wang L; Qin Q; Gao C; Zheng Y; Zhao X; Cheng X; Li Z; Zhang W; Chen H; Wang J; Yang Z; Li H; Liu H; Zhou X; Qu B; Xiang D; Guo Y; Wang L; Nie S; Fu G; Yang M; Cai S
Catheter Cardiovasc Interv; 2019 Jun; 93(7):1194-1204. PubMed ID: 31112635
[TBL] [Abstract][Full Text] [Related]
48. Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial.
Cummings J; Schwartz GG; Nicholls SJ; Khan A; Halliday C; Toth PP; Sweeney M; Johansson JO; Wong NCW; Kulikowski E; Kalantar-Zadeh K; Lebioda K; Ginsberg HN; Winblad B; Zetterberg H; Ray KK
J Alzheimers Dis; 2021; 83(4):1703-1715. PubMed ID: 34459400
[TBL] [Abstract][Full Text] [Related]
49. Impact of triglyceride-glucose index on long-term cardiovascular outcomes in patients with myocardial infarction with nonobstructive coronary arteries.
Gao S; Ma W; Huang S; Lin X; Yu M
Nutr Metab Cardiovasc Dis; 2021 Oct; 31(11):3184-3192. PubMed ID: 34511291
[TBL] [Abstract][Full Text] [Related]
50. Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Bohula EA; Wiviott SD; Giugliano RP; Blazing MA; Park JG; Murphy SA; White JA; Mach F; Van de Werf F; Dalby AJ; White HD; Tershakovec AM; Cannon CP; Braunwald E
Circulation; 2017 Dec; 136(25):2440-2450. PubMed ID: 28972004
[TBL] [Abstract][Full Text] [Related]
51. Triglyceride-glucose index predicts adverse cardiovascular events in patients with diabetes and acute coronary syndrome.
Wang L; Cong HL; Zhang JX; Hu YC; Wei A; Zhang YY; Yang H; Ren LB; Qi W; Li WY; Zhang R; Xu JH
Cardiovasc Diabetol; 2020 Jun; 19(1):80. PubMed ID: 32534586
[TBL] [Abstract][Full Text] [Related]
52. Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials).
Attar R; Wu A; Wojdyla D; Jensen SE; Andell P; Mahaffey KW; Roe MT; James SK; Wallentin L; Vemulapalli S; Alexander JH; Lopes RD; Ohman EM; Hernandez AF; Patel MR; Jones WS
Am J Cardiol; 2022 Sep; 178():11-17. PubMed ID: 35835600
[TBL] [Abstract][Full Text] [Related]
53. Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
Hamilos M; Petousis S; Xanthopoulou I; Goudevenos J; Kanakakis J; Sitafidis G; Vavouranakis M; Skalidis E; Kochiadakis G; Lekakis J; Vardas PE; Alexopoulos D
Coron Artery Dis; 2018 Jan; 29(1):53-59. PubMed ID: 28834792
[TBL] [Abstract][Full Text] [Related]
54. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
Chan CW; Yu CL; Lin JC; Hsieh YC; Lin CC; Hung CY; Li CH; Liao YC; Lo CP; Huang JL; Lin CH; Wu TJ
Cardiovasc Diabetol; 2018 Jan; 17(1):20. PubMed ID: 29368615
[TBL] [Abstract][Full Text] [Related]
55. Type 2 diabetes mellitus increases the mortality risk after acute coronary syndrome treated with coronary artery bypass surgery.
Ram E; Sternik L; Klempfner R; Iakobishvili Z; Fisman EZ; Tenenbaum A; Zuroff E; Peled Y; Raanani E
Cardiovasc Diabetol; 2020 Jun; 19(1):86. PubMed ID: 32534591
[TBL] [Abstract][Full Text] [Related]
56. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials.
Sattar N; Lee MMY; Kristensen SL; Branch KRH; Del Prato S; Khurmi NS; Lam CSP; Lopes RD; McMurray JJV; Pratley RE; Rosenstock J; Gerstein HC
Lancet Diabetes Endocrinol; 2021 Oct; 9(10):653-662. PubMed ID: 34425083
[TBL] [Abstract][Full Text] [Related]
57. How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?
Schooling CM; Zhao JV
Am J Cardiovasc Drugs; 2019 Apr; 19(2):107-111. PubMed ID: 30693439
[TBL] [Abstract][Full Text] [Related]
58. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
Jil M; Rajnikant M; Richard D; Iskandar I
Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
[TBL] [Abstract][Full Text] [Related]
59. Selective BET Protein Inhibition with Apabetalone and Cardiovascular Events: A Pooled Analysis of Trials in Patients with Coronary Artery Disease.
Nicholls SJ; Ray KK; Johansson JO; Gordon A; Sweeney M; Halliday C; Kulikowski E; Wong N; Kim SW; Schwartz GG
Am J Cardiovasc Drugs; 2018 Apr; 18(2):109-115. PubMed ID: 29027131
[TBL] [Abstract][Full Text] [Related]
60. Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome: A Randomized Clinical Trial.
Kim JM; Stewart R; Lee YS; Lee HJ; Kim MC; Kim JW; Kang HJ; Bae KY; Kim SW; Shin IS; Hong YJ; Kim JH; Ahn Y; Jeong MH; Yoon JS
JAMA; 2018 Jul; 320(4):350-358. PubMed ID: 30043065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
